Clinical study for the evaluation of the antiaging efficacy of a treatment composed of a cosmetic product and a food supplement. Controlled study vs placebo

ROELMI HPC0 sites80 target enrollmentJanuary 23, 2023

Overview

No summary available.

Registry

who.int

Start Date

January 23, 2023

End Date

July 7, 2023

Last Updated

3 years ago

Study Type

Interventional

Sex

All

Sponsor

ROELMI HPC

•1\. Healthy male and female subjects
•2\. Aged 35 to 65 years old (inclusive)
•3\. Subject showing mild\-moderate signs of skin aging (mild\-moderate skin roughness, dull skin, presence of uneven skin complexion)
•4\. 10 subjects in each group showing visible eyebags
•5\. In each group 5 Caucasian subjects, 5 South\-American/African subjects and 10 Asian subjects
•6\. Subjects who have not been involved in any other similar in the last 3 months
•7\. Subjects registered with Nation Health Service (NHS)
•8\. Subjects certifying the truthfulness of the personal data disclosed to the investigator
•9\. Subjects able to understand the language used in the investigation center and the information given by the investigator
•10\. Subjects able to respect the instructions given by the investigator as well as able to respect the study constraints and specific requirements

•1\. Subject does not meet the inclusion criteria
•2\. Subjects with acute or chronic diseases able to interfere with the outcome of the study or that are considered dangerous for the subject or incompatible with the study requirements
•3\. Subjects participating or planning to participate in other clinical trials
•4\. Subjects deprived of freedom by administrative or legal decision or under guardianship
•5\. Subjects not able to be contacted in case of emergency
•6\. Subjects admitted to a health or social facility
•7\. Subjects planning a hospitalisation during the study
•8\. Subjects who participated in a similar study without respecting an adequate washout period
•9\. Subjects having an acute, chronic or progressive illness liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
•10\. Subjects under pharmacological treatments that are considered incompatible with the study requirement by the investigator